Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients (Q34512985)

2 August 2017

Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients (English)

1 reference

2 August 2017

1 reference

6

Ulrich Andergassen

0 references

author name string

Verena Engelstaedter

1

1 reference

2 August 2017

Sabine Heublein

2

1 reference

2 August 2017

Anamur Lan Schumacher

3

1 reference

2 August 2017

Miriam Lenhard

4

1 reference

2 August 2017

Helen Engelstaedter

5

1 reference

2 August 2017

Margit Guenthner-Biller

7

1 reference

2 August 2017

Christina Kuhn

8

1 reference

2 August 2017

Brigitte Rack

9

1 reference

2 August 2017

Markus Kupka

10

1 reference

2 August 2017

Doris Mayr

11

1 reference

2 August 2017

Udo Jeschke

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

15 December 2012

1 reference

2 August 2017

1 reference

2 August 2017

12

1 reference

2 August 2017

600

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-12-600

2 August 2017

0 references

cites work

Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Use of monoclonal antibodies in the treatment of ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

CA 15-3: a prognostic marker in breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Surgery during chemotherapy and at relapse of ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Mucin gene expression in ovarian cancers.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Second-line chemotherapy for recurrent carcinoma of the ovary.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Targeting the human MUC1 oncoprotein: a tale of two proteins

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-600

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-600

The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-600

Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-600

Where do we place PankoMab in the reagents used to study the MUC1 superfamily?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-600

Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3582552

Expression of aberrantly glycosylated Mucin-1 in ovarian cancer

27 October 2018

1 reference

12 December 2020

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

1 reference

12 December 2020

Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas

1 reference

12 December 2020

MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?

1 reference

12 December 2020

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

1 reference

12 December 2020

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

12 December 2020

Expression of MUC1 and MUC2 Mucins by Human Tumor Cell Lines

1 reference

12 December 2020

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

1 reference

12 December 2020

Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer

1 reference

12 December 2020

Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer

1 reference

12 December 2020

Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer

1 reference

12 December 2020

Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-12-600

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference